NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
Clinical Trials
194 trialsNCT06258096 2024-02-14
LI-TASTE
Academic Centre for Dentistry in Amsterdam
Phase NA Unknown
NCT05840107 2024-02-13
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT05478993 2024-01-31
SPODUMENE
Peking University People's Hospital
Phase 2 Unknown
NCT06205823 2024-01-16
CAREMM-2305
Seoul St. Mary's Hospital
Unknown
NCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT04727008 2023-12-12
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Sichuan University
Phase 1 Unknown
NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT06116734 2023-11-03
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Unknown
NCT05378971 2023-10-04
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
LanZhou University
Phase NA Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT04309981 2023-08-28
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 1/2 Unknown
NCT05995808 2023-08-16
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Sohag University
Phase NA Unknown
NCT04211259 2023-08-07
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Unknown
NCT05964270 2023-07-27
ITUMM
Isala
Phase NA Unknown
NCT04143932 2023-07-18
THD-MM-Reg
Turkish Hematology Association
Unknown
NCT04836871 2023-07-13
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
Phase 1 Unknown
NCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
NCT04814615 2023-06-27
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Hoag Memorial Hospital Presbyterian
Phase 2 Unknown
NCT03809780 2023-06-22
LENDER
Kosin University Gospel Hospital
Phase 2 Unknown
NCT05855122 2023-06-02
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT05857982 2023-05-15
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT05858203 2023-05-15
AATF/Che-1
Regina Elena Cancer Institute
Unknown
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05749133 2023-04-20
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT05438394 2023-04-14
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Peking University People's Hospital
Phase 1 Unknown
NCT05802992 2023-04-07
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Phase 3 Unknown
NCT05739188 2023-02-23
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05740891 2023-02-23
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
Zhejiang University
Phase 1 Unknown
NCT03946332 2023-02-08
PAMAL
Centre Hospitalier Universitaire, Amiens
Phase NA Unknown
NCT05718401 2023-02-08
The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
First Affiliated Hospital Xi'an Jiaotong University
Unknown
NCT04706936 2023-02-06
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05432414 2023-01-31
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Phase 2 Unknown
NCT05693012 2023-01-20
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05655676 2022-12-19
89Zr-labeled NY008 PET Imaging in Patients
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1 Unknown
NCT05266768 2022-11-30
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
Tongji Hospital
Phase 1 Unknown
NCT05577884 2022-11-08
Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma
Seoul National University Hospital
Unknown
NCT05016778 2022-11-01
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05578625 2022-10-13
ctDNA Methylation Sequencing for Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Unknown
NCT04352556 2022-09-23
COVID19-hematological Malignancies: the Italian Hematology Alliance
Ospedale di Circolo - Fondazione Macchi
Unknown
NCT05549973 2022-09-22
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
NCT05548686 2022-09-21
ALGOMYELOMOV
University Hospital, Caen
Phase NA Unknown
NCT05218603 2022-09-16
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
PETHEMA Foundation
Unknown
NCT05536700 2022-09-13
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Unknown
NCT03336073 2022-09-07
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation
Phase 2 Unknown